ClinicalTrials.gg

Program

annamycin

Also written as “Liposomal Annamycin”, “Liposomal Annamycin Injection in combination with Cytarabine Injection” and “Liposomal Annamycin for Injection in combination with Cytarabine Injection.”.

Its studies are mostly in Leukemia, Myeloid, Acute · Precursor Cell Lymphoblastic Leukemia-Lymphoma · Sarcoma, led by 2 companies.

Furthest: phase 3, since Dec 5, 20247 company-led studies, 1 open or runningNext primary completion: Aug 2029 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Moleculin Biotech51 open or runningphase 3since Dec 5, 2024Oct 16, 2017Aug 2029phase 3 · NCT06788756
Callisto Pharmaceuticals20 open or runningphase 2since Dec 29, 2005Dec 29, 2005none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 29, 2005First study: phase 2 study in Precursor Cell Lymphoblastic Leukemia-LymphomaNew to Callisto PharmaceuticalsCallisto Pharmaceuticals · NCT00271063 · 34 enrolled · United States
  2. Jan 30, 2007Phase 1 study in Precursor Cell Lymphoblastic Leukemia-LymphomaCallisto Pharmaceuticals · NCT00430443 · 3 enrolled · United States
  3. Oct 16, 2017Moleculin Biotech's first study: phase 2 study in Leukemia, Myeloid, AcuteNew to Moleculin BiotechMoleculin Biotech · NCT03315039 · 7 enrolled · United States
  4. Dec 25, 2017Phase 2 study in Leukemia, Myeloid, AcuteMoleculin Biotech · NCT03388749 · 20 enrolled · Poland
  5. May 4, 2021Phase 2 study in SarcomaMoleculin Biotech · NCT04887298 · 36 enrolled · United States
  6. Feb 22, 2022Phase 2 study in Leukemia, Myeloid, AcuteMoleculin Biotech · NCT05319587 · 22 enrolled · Italy, Poland
  7. Dec 5, 2024Phase 3 study in Leukemia, Myeloid, AcuteMoleculin Biotech · NCT06788756 · 312 planned · United States, Czechia, Georgia and more

Ahead

  1. Aug 2029Primary completion: phase 3 study in Leukemia, Myeloid, AcuteMoleculin Biotech · NCT06788756

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06788756Leukemia, Myeloid, Acute · United States, Czechia, Georgia and more3RecruitingMoleculin BiotechAug 2029312
NCT05319587Leukemia, Myeloid, Acute · Italy, Poland2CompletedMoleculin BiotechAug 2, 202322
NCT04887298Sarcoma · United States2CompletedMoleculin BiotechSep 29, 202236
NCT03388749Leukemia, Myeloid, Acute · Poland2CompletedMoleculin BiotechFeb 8, 202220
NCT03315039Leukemia, Myeloid, Acute · United States2CompletedMoleculin BiotechJan 14, 20207
NCT00430443Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States1TerminatedCallisto Pharmaceuticals3
NCT00271063Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States2UNKNOWNCallisto Pharmaceuticals34

How it is read

Names in the registry

  • “Liposomal Annamycin”, 5 entries
  • “Liposomal Annamycin Injection in combination with Cytarabine Injection”, 2 entries
  • “Liposomal Annamycin for Injection in combination with Cytarabine Injection.”, 1 entry
  • “Liposomal Annamycin (L-Annamycin)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
annamycin (Moleculin Biotech): development program | ClinicalTrials.gg